A Phase 1 interventional study of Alisertib in Advanced Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.
The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days. This open label study enrolled 87 participants. Participants were enrolled in one of 3 treatment groups:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted before Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
Drug: Alisertib
Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
Drug: Alisertib
Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
Drug: Alisertib
Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
Also known as: MLN8237
Number of Participants With Dose-Limiting Toxicity (DLT)
DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib: 1. Grade 4 neutropenia lasting ≥7 consecutive days 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>1 week due to failure of adequate hematologic or nonhematologic recovery from previous cycle of treatment 8. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.
Time frame: Cycle 1 Day 1 up to Day 35 (alisertib daily for 7 to 21 days followed by a 14-day recovery period)
Maximum Tolerated Dose (MTD) of Alisertib
MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 patients.
Time frame: From first dose of study drug to 30 days after the last dose (up to 1011 days)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From first dose of study drug to 30 days after the last dose (up to 1011 days)
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
AUCt: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
AUCt: Area Under the Concentration--Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Terminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 14 predose and at multiple time-points (up to 10 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 10 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints (up to 10 hours) postdose
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 8
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame: Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame: Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Cmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 7 Days (QD7D) Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 7 Days (QD7D) Dosing
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 14 Days (QD14D) Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 14 Days (QD14D) Dosing
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 21 Days (QD21D) Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 21 Days (QD21D) Dosing
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 7, 6 hours postdose
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
Time frame: Baseline and Cycle 1 Day 7, 6 hours postdose
Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype patients for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.
Time frame: Cycle 1 Day 1 predose
Best Overall Response Based on Investigator Assessment
Best overall response is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target and nontarget lesions and normalization of tumor marker level (if applicable); PR is defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Time frame: Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)
Duration Of Response (DOR)
DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.
Time frame: Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)
Effect of Food on the Pharmacokinetics (PK) of Alisertib
The effects of food on the PK of alisertib were to be evaluated using the preferred alisertib regimen (unit dose and formulation) based on the results from the relative bioavailability study.
Time frame: Up to 6 months
Participants took part in the study at 3 investigative sites in the United States from 15 May 2007 to 23 February 2011.
| Milestone | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability |
|---|---|---|---|
| Started | 65 | 2 | 20 |
| Completed | 0 | 0 | 0 |
| Not completed | 65 | 2 | 20 |
| Withdrew: Occurrence of adverse event(s) | 10 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 2 | 0 | 0 |
| Withdrew: Progressive disease | 41 | 2 | 15 |
| Withdrew: Patient declined further treatment | 0 | 0 | 3 |
| Withdrew: Symptomatic deterioration | 2 | 0 | 0 |
| Withdrew: Reason not specified | 10 | 0 | 2 |
DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib: 1. Grade 4 neutropenia lasting ≥7 consecutive days 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>1 week due to failure of adequate hematologic or nonhematologic recovery from previous cycle of treatment 8. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.
| participants | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D | Alisertib 25 mg PIC QD 14D | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D | Alisertib 40 mg PIC BID 14D | Alisertib 10 mg ECT QD7 | Alisertib 20 mg ECT QD7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 0 | 0 |
MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 patients.
| mg BID for 7 Days | Alisertib |
|---|---|
| Maximum Tolerated Dose (MTD) of Alisertib | 50 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability |
|---|---|---|---|
| AEs | 65 | 2 | 20 |
| SAEs | 26 | 0 | 1 |
| nM | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 208.4 ± 27.96 | 279.1 ± 46.20 | 759.3 ± 11.82 | 1245.4 ± 20.60 | 1661.3 ± 45.20 | 2717.8 ± 44.62 | 4260.3 ± 42.62 |
| Day 7 | 285.7 ± 32.74 | 931.5 ± 81.68 | 1114.1 ± 36.96 | 1681.6 ± 64.62 | 2376.3 ± 51.06 | 3586.4 ± 48.28 | 4467.8 ± 24.58 |
| hours (h) | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 2.000 (1.50 to 3.00) | 2.000 (1.50 to 3.00) | 1.500 (1.50 to 1.50) | 2.000 (1.50 to 6.00) | 2.000 (1.50 to 3.00) | 2.000 (1.48 to 5.57) | 2.000 (1.45 to 3.00) |
| Day 7 | 1.500 (1.00 to 1.50) | 3.750 (1.50 to 6.00) | 1.500 (1.50 to 2.00) | 2.000 (1.97 to 6.00) | 2.000 (1.98 to 3.05) | 3.710 (1.42 to 6.02) | 2.000 (1.48 to 3.93) |
| nM*h | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Day 1 | 1682.4 ± 31.06 | 2525.8 ± 21.87 | 5772.1 ± 10.68 | 12045.4 ± 57.01 | 20958.1 ± 38.92 | 29460.7 ± 39.43 | 38582.1 ± 45.95 |
| Day 7 | 2919.5 ± 32.31 | 10602.9 ± 107.87 | 10927.5 ± 45.27 | 21976.0 ± 96.64 | 27825.5 ± 53.59 | 46271.1 ± 33.38 | 53031.9 ± 26.22 |
| h | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 24.950 ± 20.4354 | 35.150 ± 23.4052 | 26.400 ± 19.7684 | 18.155 ± 12.5087 | 39.333 ± 18.8006 | 13.427 ± 4.3465 | 16.766 ± 9.7804 |
| ratio | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 1.753 ± 0.2754 | 6.350 ± 7.2408 | 2.037 ± 0.9708 | 1.997 ± 0.9393 | 1.535 ± 0.3323 | 1.677 ± 0.6788 | 1.588 ± 0.4129 |
| ratio | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 4.107 ± 0.8460 | 5.195 ± 3.9527 | 5.430 ± 2.4856 | 3.907 ± 2.3944 | 3.850 ± 2.0612 | 4.922 ± 2.5890 | 4.610 ± 0.5314 |
| liters (L)/h | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 3.302 ± 35.8915 | 1.817 ± 107.8347 | 3.525 ± 49.1267 | 3.511 ± 72.1346 | 5.545 ± 41.0258 | 4.348 ± 61.5266 | 5.450 ± 37.3021 |
| ng | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 4806.7 ± 8325.39 | 18815.0 ± 1675.84 | 13813.3 ± 16387.22 | 14473.3 ± 15603.71 |
| L/h | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|
| CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing | 0.0012630 ± NA | 0.0013860 ± NA | 0.0009414 ± 0.00063956 | 0.0006710 ± 0.00060091 |
| nM | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 1 | 778.7 ± 24.28 |
| Day 7 | 995.5 ± 43.21 |
| Day 14 | 808.9 ± 37.96 |
| h | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 1 | 4.000 (2.00 to 8.88) |
| Day 7 | 2.000 (2.00 to 2.00) |
| Day 14 | 2.000 (1.098 to 2.00) |
| nM*h | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 1 | 8061.6 ± 17.30 |
| Day 7 | 8634.0 ± 42.70 |
| Day 14 | 8978.0 ± 20.15 |
| h | Alisertib 25 mg PIC QD 14D |
|---|---|
| Terminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing | 65.67 ± 43.859 |
| ratio | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 7 | 1.203 ± 0.6964 |
| Day 14 | 1.133 ± 0.2303 |
| ratio | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 7 | 6.877 ± 1.1151 |
| Day 14 | 5.073 ± 2.2113 |
| L/h | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 7 | 6.030 ± 2.9963 |
| Day 14 | 5.433 ± 0.9808 |
| ng | Alisertib 25 mg PIC QD 14D |
|---|---|
| Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing | 800.0 ± 1385.64 |
| L/h | Alisertib 25 mg PIC QD 14D |
|---|---|
| CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing | 0.0004930 ± NA |
| nM | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 1 | 898.2 ± 86.35 | 1725.9 ± 54.70 | 2237.0 ± 54.18 |
| Day 14 | 1343.3 ± 60.32 | 1722.0 ± 38.82 | 2598.3 ± 12.49 |
| Day 21 | 1104.7 ± 45.15 | 1564.2 ± 38.80 | 1974.5 ± 59.49 |
| h | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 1 | 2.020 (2.00 to 4.00) | 2.285 (2.00 to 4.00) | 2.000 (2.00 to 2.02) |
| Day 14 | 2.000 (2.00 to 2.18) | 2.000 (1.98 to 2.03) | 2.000 (2.00 to 2.05) |
| Day 21 | 2.000 (1.00 to 2.02) | 2.000 (1.93 to 9.92) | 2.000 (1.00 to 6.00) |
| nM*h | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 1 | 10058.0 ± 66.85 | 14686.6 ± 44.04 | 22114.8 ± 68.66 |
| Day 14 | 15131.7 ± 49.89 | 17168.2 ± 32.09 | 23197.2 ± 17.75 |
| Day 21 | 13199.3 ± 70.05 | 19336.3 ± 26.85 | 23499.8 ± 65.64 |
| h | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing | 31.667 ± 6.7122 | 23.650 ± 16.9487 | 22.378 ± 19.8802 |
| ratio | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 14 | 1.560 ± 0.5543 | 1.230 ± 0.4193 | 1.440 ± 0.1493 |
| Day 21 | 1.560 ± 1.0516 | 1.373 ± 0.4474 | 1.335 ± 0.4749 |
| ratio | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 14 | 4.773 ± 0.9001 | 7.543 ± 5.4982 | 6.392 ± 2.0824 |
| Day 21 | 3.637 ± 1.8675 | 4.157 ± 2.1051 | 5.570 ± 2.5772 |
| L/h | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 14 | 3.181 ± 42.5706 | 5.612 ± 28.6881 | 5.825 ± 17.7291 |
| Day 21 | 3.656 ± 89.5750 | 4.984 ± 25.6945 | 5.745 ± 42.3818 |
| ng | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing | 3047.7 ± 5278.71 | 5766.7 ± 7971.95 | 9391.4 ± 11410.18 |
| L/h | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing | 0.0008640 ± NA | 0.0012323 ± 0.00111840 | 0.0007865 ± 0.00042447 |
| nM | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Day 1 | 1581.1 ± 37.34 | 1867.1 ± 29.03 |
| Day 7 | 3376.4 ± 41.74 | 3080.8 ± 38.79 |
| h | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Day 1 | 2.000 (1.98 to 8.00) | 2.000 (1.60 to 4.00) |
| Day 7 | 2.015 (0.98 to 6.05) | 2.000 (1.98 to 6.03) |
| nM*h | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Day 1 | 11166.3 ± 37.45 | 13200.4 ± 26.70 |
| Day 7 | 32291.5 ± 40.82 | 27386.1 ± 37.43 |
| h | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 20.215 ± 15.5083 | 18.200 ± 3.2212 |
| ratio | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 2.474 ± 1.0467 | 2.543 ± 0.1950 |
| ratio | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 2.193 ± 1.1346 | 1.890 ± 0.2012 |
| L/h | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 2.984 ± 43.8719 | 4.220 ± 47.9681 |
| ng | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 13775.0 ± 7937.14 | 8498.3 ± 6866.09 |
| ng | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing | 0.001 ± 0.0011 | 0.001 ± 0.0004 |
| nM | Alisertib 40 mg PIC BID 14D |
|---|---|
| Day 1 | 1236.6 ± 37.29 |
| Day 7 | 2060.0 ± NA |
| h | Alisertib 40 mg PIC BID 14D |
|---|---|
| Day 1 | 3.00 (2.0 to 4.0) |
| Day 7 | 1.70 (1.7 to 1.7) |
| nM*h | Alisertib 40 mg PIC BID 14D |
|---|---|
| AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing | 9684.8 ± 71.50 |
| nM*h | Alisertib 40 mg ECT BID 7D | Alisertib 40 mg PIC BID 7D |
|---|---|---|
| AUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7 | 12700.0 ± 6557.58 | 14190.7 ± 7097.72 |
| nM | Alisertib 40 mg ECT BID 7D | Alisertib 40 mg PIC BID 7D |
|---|---|---|
| Cmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7 | 1666.1 ± 765.28 | 2027.9 ± 928.96 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| mitotic cells/millimeter of BEL | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Day 1, Hour 6 | 0.405 ± 0.2701 | 0.614 ± 0.5437 | 0.263 ± 0.1461 | 0.168 ± 0.5146 | 0.488 ± 1.0215 | 0.261 ± 0.4597 | 0.865 ± 0.9420 |
| Day 1, Hour 24 | 0.019 ± 0.1914 | -0.103 ± 0.0186 | 0.005 ± 0.0709 | 0.141 ± 0.3852 | 0.108 ± 0.4081 | 1.764 ± 2.6380 | 0.239 ± 0.6992 |
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
| apoptotic cells/millimeter of BEL | Alisertib 5 mg PIC QD 7D | Alisertib 10 mg PIC QD 7D | Alisertib 20 mg PIC QD 7D | Alisertib 40 mg PIC QD 7D | Alisertib 80 mg PIC QD 7D | Alisertib 110 mg PIC QD 7D | Alisertib 150 mg PIC QD 7D |
|---|---|---|---|---|---|---|---|
| Day 1, Hour 6 | 0.010 ± 0.1175 | -0.090 ± 0.1278 | 0.042 ± 0.0731 | 0.040 ± 0.0701 | 0.121 ± 0.1317 | 0.036 ± 0.0530 | -0.042 ± 0.1262 |
| Day 1, Hour 24 | 0.009 ± 0.1164 | 0.065 ± 0.1404 | 0.000 ± 0.0000 | 0.037 ± 0.0634 | 0.074 ± 0.1286 | 0.151 ± 0.1721 | 0.139 ± 0.2069 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| mitotic cells/millimeter of BEL | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 1, Hour 6 | 0.134 ± 0.1723 |
| Day 1, Hour 24 | 0.047 ± 0.0589 |
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
| apoptotic cells/millimeter of BEL | Alisertib 25 mg PIC QD 14D |
|---|---|
| Day 1, Hour 6 | 0.000 ± 0.0000 |
| Day 1, Hour 24 | 0.000 ± 0.0000 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| mitotic cells/millimeter of BEL | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 1, Hour 6 | 0.380 ± 0.4165 | 0.405 ± 0.4690 | 0.510 ± NA |
| Day 1, Hour 24 | 0.021 ± 0.1081 | 0.082 ± 0.1796 | 0.289 ± 0.5746 |
| Day 7, Hour 6 | — | — | 0.479 ± 0.3040 |
| Day 21, Hour 6 | — | 0.045 ± NA | 0.742 ± 0.5782 |
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
| apoptotic cells/millimeter of BEL | Alisertib 25 mg PIC QD 21D | Alisertib 50 mg PIC QD 21D | Alisertib 70 mg PIC QD 21D |
|---|---|---|---|
| Day 1, Hour 6 | 0.122 ± 0.2117 | 0.000 ± 0.0000 | 0.000 ± NA |
| Day 1, Hour 24 | 0.042 ± 0.0722 | 0.042 ± 0.0719 | 0.000 ± 0.0000 |
| Day 7, Hour 6 | — | — | 0.000 ± 0.0000 |
| Day 21, Hour 6 | — | 0.099 ± NA | 0.032 ± 0.0552 |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| mitotic cells/millimeter of BEL | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Day 1, Hour 6 | 0.054 ± 0.3022 | 0.364 ± 0.2574 |
| Day 1, Hour 24 | 2.578 ± 2.2875 | 1.435 ± 0.8329 |
| Day 7, Hour 6 | 5.486 ± 5.8688 | — |
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
| apoptotic cells/millimeter of BEL | Alisertib 50 mg PIC BID 7D | Alisertib 60 mg PIC BID 7D |
|---|---|---|
| Day 1, Hour 6 | -0.016 ± 0.0494 | 0.020 ± 0.0491 |
| Day 1, Hour 24 | 0.055 ± 0.1691 | 0.080 ± 0.1958 |
| Day 7, Hour 6 | 2.142 ± 3.2510 | — |
Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.
| mitotic cells/millimeter of BEL | Alisertib 40 mg PIC BID 14D |
|---|---|
| Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing | 1.507 ± NA |
Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.
| apoptotic cells/millimeter of BEL | Alisertib 40 mg PIC BID 14D |
|---|---|
| Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing | 2.837 ± NA |
One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype patients for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.
| participants | Alisertib |
|---|---|
| wt/wt | 38 |
| wt/*28 | 30 |
| *28/*28 | 9 |
| *28/other | 4 |
| other/other | 2 |
| Not Determined | 1 |
| Missing | 3 |
Best overall response is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target and nontarget lesions and normalization of tumor marker level (if applicable); PR is defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
| percentage of participants | Alisertib |
|---|---|
| Best Overall Response Based on Investigator Assessment | 1 |
DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.
| days | Alisertib |
|---|---|
| Duration Of Response (DOR) | 470 |
The effects of food on the PK of alisertib were to be evaluated using the preferred alisertib regimen (unit dose and formulation) based on the results from the relative bioavailability study.
No measurements were reported for this outcome.
Collected over From first dose of study drug to 30 days after the last dose (up to 1011 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PIC Dose Escalation | — | 26/65 (40%) | 65/65 (100%) |
| ECT Dose Escalation | — | 0/2 (0%) | 2/2 (100%) |
| Relative Bioavailability | — | 1/20 (5%) | 20/20 (100%) |
| Event | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/65 | 0/2 | 1/20 |
| AnaemiaBlood and lymphatic system disorders | 4/65 | 0/2 | 0/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/65 | 0/2 | 0/20 |
| Klebsiella bacteraemiaInfections and infestations | 1/65 | 0/2 | 1/20 |
| Enterococcal bacteraemiaInfections and infestations | 0/65 | 0/2 | 1/20 |
| Bile duct obstructionHepatobiliary disorders | 0/65 | 0/2 | 1/20 |
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 0/2 | 1/20 |
| Back painMusculoskeletal and connective tissue disorders | 0/65 | 0/2 | 1/20 |
| Neck painMusculoskeletal and connective tissue disorders | 0/65 | 0/2 | 1/20 |
| Deep vein thrombosisVascular disorders | 0/65 | 0/2 | 1/20 |
| Event | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability |
|---|---|---|---|
| FatigueGeneral disorders | 32/65 | 2/2 | 12/20 |
| AnaemiaBlood and lymphatic system disorders | 24/65 | 2/2 | 6/20 |
| NauseaGastrointestinal disorders | 39/65 | 1/2 | 6/20 |
| DiarrhoeaGastrointestinal disorders | 34/65 | 1/2 | 6/20 |
| VomitingGastrointestinal disorders | 24/65 | 1/2 | 2/20 |
| StomatitisGastrointestinal disorders | 15/65 | 1/2 | 5/20 |
| Oral painGastrointestinal disorders | 3/65 | 1/2 | 0/20 |
| AstheniaGeneral disorders | 11/65 | 1/2 | 1/20 |
| PainGeneral disorders | 1/65 | 1/2 | 1/20 |
| AnorexiaMetabolism and nutrition disorders | 30/65 | 1/2 | 3/20 |
The Safety Population included all participants who received any amount of study drug.
| Age, Continuous(years) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 10.44 | 57.0 ± 15.56 | 56.9 ± 11.71 | 60.4 ± 10.88 |
| Sex: Female, Male(Participants) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Female | 33 | 1 | 9 | 43 |
| Male | 32 | 1 | 11 | 44 |
| Race/Ethnicity, Customized(participants) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 56 | 2 | 20 | 78 |
| Not Reported | 7 | 0 | 0 | 7 |
| Hispanic or Latino | 2 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(participants) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| White | 55 | 2 | 18 | 75 |
| Black or African American | 9 | 0 | 2 | 11 |
| Other | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| United States | 65 | 2 | 20 | 87 |
| Height(cm) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Mean | 169.3 ± 10.06 | 165.1 ± 0.00 | 171.5 ± 12.51 | 169.7 ± 10.55 |
| Weight(kg) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Mean | 78.24 ± 18.130 | 67.36 ± 11.226 | 83.97 ± 21.706 | 79.33 ± 18.976 |
| Body Surface Area (BSA)(m^2) | PIC Dose Escalation | ECT Dose Escalation | Relative Bioavailability | Total |
|---|---|---|---|---|
| Mean | 1.91 ± 0.263 | 1.75 ± 0.147 | 1.99 ± 0.294 | 1.92 ± 0.270 |
Ran from May 2007 to primary completion in Aug 2010, 38 months.
Results were first posted in Mar 2019, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →